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From the Editor’s Desk
GIVE US YOUR RICH!
This report has demonstrated, we hope 
convincingly, that, unless significant changes 
are made, careers in medicine may not be 
affordable or attractive within the next few 
decades, and that applicants from lower 
socio-economic groups may choose not to 
pursue careers in medicine because of their 
concerns about educational costs.*
Experts claim that the delivery of health 
care is best achieved when the mix of the 
medical workforce mirrors that of the 
society it serves.
However, this balance is under threat in 
the United Kingdom and the United States, 
where the cost and duration of medical 
education are increasingly forming a barrier 
for students from lower socioeconomic 
backgrounds. In the US, 60 per cent of 
medical students come from families in the 
top income bracket; becoming an MD is 
apparently beyond the reach of most middle 
and working class families. And no wonder! 
A US medical education costs about 
US$120 000 in public medical schools 
and US$225 000 in private schools. 
With Australia’s recent move towards 
full-fee-paying medical students, we may 
well wonder whether we are set to mimic 
the American way.
In Australian medical schools, fees range 
from A$31 000 to A$36 000 per year for 
5–6-year undergraduate programs and from 
A$25 000 to A$35 520 per year for 4-year 
graduate-entry programs. Shackled with 
these debts, full-fee-paying students, like 
their US counterparts, are more likely to 
train in high-income specialties.
America’s Statue of Liberty proudly 
proclaims the message, “give us your poor”. 
Paradoxically, the message of US medical 
schools might now be “give us your rich”.
The American experience is a cautionary 
tale. Are our current policies an experiment 
in social engineering, guaranteeing the loss 
of Australia’s cherished egalitarianism and 
tradition of the “fair go”?
Martin B Van Der Weyden
* Medical education costs and student debt: a 
working group report to the AAMC Governance. 
Washington, DC: Association of American Medical 
Colleges, 2005.
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Matters Arising
Barriers in the quest for quality drug information: salutary lessons 
from TGA-approved sources for thyroid-related medications
A recent article drawing attention to the “inadequate, inaccurate or outdated” product information available for 
thyroid-related drugs prompted letters from several of our readers. (MJA 2007; 186: 76-79)
Deficiencies in drug 
interaction information
Michelle Sweidan and James F Reeve
TO THE EDITOR: The National Prescribing
Service recently reviewed drug interaction
information in a range of prescribing and
dispensing software systems and reference
sources, including the Therapeutic Goods
Administration (TGA)-approved product
information (PI). Our findings support those
of Stockigt1 regarding the quality of informa-
tion in PI.
An expert panel (see Acknowledgements)
assessed 40 pairs of potentially interacting
drugs (20 clinically important and 20 minor
interactions) by examining the “Interactions”
section of 80 PI monographs. The panel
assessed both detection and content, using a
range of parameters considered to be impor-
tant in clinical decision making. For the clini-
cally important drug interactions, these
included useful management information
(defined as sufficient information to proceed
without looking elsewhere), pharmacological
mechanism of interaction, clinical effects of the
interaction, and time frame (onset, duration).
For clinically important interactions, 38 of
40 PI monographs listed the potential interac-
tion; however, there were considerable short-
comings in the amount and quality of
information provided. Only five of 38 mono-
graphs (13%) provided useful information
about management. The mechanism was
described in 15 monographs (39%) and clini-
cal effects in 19 (50%); time frame was men-
tioned in only one (3%). In addition, there
were many inconsistencies between any two
monographs for a particular drug pair — not
surprising given that the information is usually
developed by different drug manufacturers at
different times.
The results of our study suggest that in
many cases the PI for a drug does not provide
useful information about potential drug inter-
actions. For decision support to be useful to
health practitioners, information must be suffi-
ciently detailed and relevant. Poor quality,
irrelevant or inconsistent information is at best
unhelpful or a waste of time, and at worst may
prompt an inappropriate management deci-
sion, potentially compromising patient care.
While epidemiological evidence for drug inter-
actions is limited, good quality information
and practical advice is available in a number of
specialised drug interactions reference sources.
This issue will be discussed in more detail with
the full results of our study, which will be
submitted for publication later this year.
Acknowledgements: We worked with an expert
panel on this project: Professor Jo-anne Brien (Clini-
cal and Academic Pharmacist), Dr Pradeep Jayasuriya
(General Practitioner), Dr Jennifer Martin (Physician
and Clinical Pharmacologist), and Mr Graeme Vernon
(Drug Information Pharmacist).
Michelle Sweidan, Project Officer
James F Reeve, Program Manager
Pharmaceutical Decision Support Program, 
National Prescribing Service, Melbourne, VIC.
msweidan@nps.org.au
1 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust
2007; 186: 76-79. ❏
Specialist societies can assist
Leon A Bach
TO THE EDITOR: On behalf of the Endo-
crine Society of Australia, I would like to
endorse the views expressed by Stockigt that
the Therapeutic Goods Administration (TGA)-
approved information sources for thyroid-
related medications are outdated.1 His exam-
ples are compelling evidence that statements
within product information (PI) sources are
inconsistent with current practice. The conse-
quences of these statements range from con-
fusing to potentially dangerous.
The current process for updating PI appears
to exclude expert advice from specialist practi-
tioners who are most likely to be aware of
recent developments regarding the use of
medications specific to their practice. In most
areas of medicine, specialist societies repre-
senting these practitioners provide an excellent
potential “first port of call” for the TGA and
suppliers to source expert, evidence-based
assistance in updating PI. Certainly, the Endo-
crine Society of Australia is willing to act in this
capacity for endocrine-related drugs, and I
would be very surprised if this were not the
case for other specialist societies.
In summary, a partnership between all par-
ties involved in the provision of quality care is
needed to ensure that PI is contemporary and
accurate.
Leon A Bach, Professor
Department of Medicine, Monash University, 
Alfred Hospital, Melbourne, VIC.
Leon.Bach@med.monash.edu.au
1 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust




TO THE EDITOR: I concur with Professor
Stockigt’s recent article1 outlining the short-
comings of product information (PI) for thy-
roid-related drugs. I often need to contradict
incorrect or even hazardous PI advice given to
patients.
An example is the consumer medicine
information (CMI) available on the MIMS
website, the “myDr” service.2 Although
Hysone (hydrocortisone, Alphapharm) is often
used for cortisol replacement, rather than as
anti-inflammatory therapy, much of the CMI
makes no distinction between these two uses.
This may, in part, underlie the potentially
dangerous advice: “Do not take Hysone if you
have any infections that are not being treated
or are not responding to treatment”.2 This
instruction implies that patients should stop
taking Hysone when they have an infection;
this may be disastrous for those with adrenal
insufficiency because it could lead to an adre-
nal crisis.3 It is necessary to increase replace-
ment dosages in the event of an infection,
intercurrent illness or surgery.3
The CMI for Cortate (cortisone acetate,
Aspen Pharmacare), the alternative glucocorti-
coid replacement drug, has similar informa-
tion: “Do not take CORTATE if you have an
uncontrolled infection”.4
In the editorial accompanying Stockigt’s
article,5 Dowden acknowledges that PI needs
to be kept up to date, but I think that PI and
CMI will remain inadequate without expert
professional review, in addition to that cur-
rently mandated by the Therapeutic Goods
Administration.
Patients with adrenal insufficiency need reli-
able information about the replacement medi-
cations they take long term. The CMI for theseMJA • Volume 186 Number 9 • 7 May 2007 483
MATTERS ARISINGtwo drugs is in need of urgent revision in the
interests of patient safety.
David Torpy, Associate Professor
Endocrine and Metabolic Unit, Royal Adelaide 
Hospital, Adelaide, SA.
dtorpy@mail.rah.sa.gov.au
1 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust
2007; 186: 76-79. 




3 Stewart PM. The adrenal cortex. In: Reed Larsen P,
Kronenberg HM, Melmed S, Polonsky KS, editors.
Williams textbook of endocrinology. 10th ed. WB
Saunders, 2003: 531-532.




5 Dowden JS. Product information past perfect
[editorial]. Med J Aust 2007; 186: 51-52. ❏
MIMS is not a stand-alone 
resource
Elizabeth A Donohoo
TO THE EDITOR: The discussion regarding
increased currency and updating of prescrip-
tion drug information (product information,
PI)1 provides on opportunity for insightful and
valuable debate. MIMS (a compilation of PI)2
supports any initiatives that result in PI and
consumer medicine information (CMI) being
updated more regularly, and I would like to
clarify MIMS’ specific role in the process.
PI is an invaluable information source, but
not the only source. Accordingly, MIMS was
never intended to be used as a stand-alone
resource, without appropriate clinical experi-
ence and reference to other resources, where
warranted. Although this was not mentioned
in Stockigt’s article,1 it is clearly stated on the
Foreword page of MIMS annual.2
Stockigt, in various comments he made to
the media, observed that his article reviewed
only one class of drugs1 — thyroid medication
— which has been notable for its lack of new
products or information in recent years. Thus,
his findings cannot be extrapolated across the
entire pharmaceutical database. Dowden’s
editorial,3 however, appears to suggest that
outdated PI is common. This is an assertion
with which MIMS must strongly disagree.
One measure of the currency of a medicine
information database is the frequency and
number of updates. MIMS currently publishes
more than 100 changes to PI every month,
and has the processes and people in place to
make an even greater number of changes more
frequently should this information become
available. However, ultimately the responsibil-
ity for updating PI lies with the pharmaceutical
industry, and all changes must be approved by
the Therapeutic Goods Administration; only
then can PI be disseminated by MIMS.
MIMS believes that PI, while a valuable
resource, is not a stand-alone resource. This is
supported by the fact that the entire range of
MIMS electronic decision-support modules,
such as MIMS DrugAlert (drug–drug interac-
tions) and MIMS AllergyAlert (drug–allergy
warnings), are, in fact, derived from reviews of
the primary international literature. MIMS
welcomes the opportunity to discuss this
perspective.
Elizabeth A Donohoo, Managing Editor
MIMS, Sydney, NSW.
elizabeth.donohoo@mims.com.au
1 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust
2007; 186: 76-79. 
2 MIMS annual. 30th ed. Sydney: CMPMedica Australia,
2006.
3 Dowden JS. Product information past perfect
[editorial]. Med J Aust 2007; 186: 51-52. ❏
The National Prescribing 
Service should lead
Jim R Stockigt
IN REPLY: It is encouraging that Donohoo,
on behalf of MIMS, supports initiatives to
more regularly update product information
(PI). My review1 demonstrates that necessity.
The material published by MIMS is apparently
not under their direct editorial control; it
depends on PI from the pharmaceutical indus-
try, vetted by the Therapeutic Goods Adminis-
tration. Revision of PI by drug sponsors has
major inertia.2
While the problems in the thyroid area can
be serious for a fraction, perhaps 1%–2% per
year, of the 200000 people who take thyroid
medications, I made no assertion that the
deficiencies identified for thyroid-related med-
ications reflect other PI-based information;
that question remains open.
Donohoo emphasises that the PI-based
information in MIMS is not a stand-alone
resource for health professionals, who are able
to choose between sources of drug informa-
tion. By contrast, consumers are offered PI-
based consumer medicine information (CMI)
as a definitive resource, without choice. The
obligatory link between PI and CMI3 is a
compelling reason for revision of PI.
In my view, the National Prescribing Serv-
ice, an organisation that publishes the journal
Australian Prescriber and fosters quality use of
medicines, is the national resource best placed
to show initiative to improve the current
deplorable state of thyroid-related PI which is,
in my view, an impediment to safe, well
informed health care for some thousands of
Australians. Together with Donohoo, I support
debate and initiative.
Jim R Stockigt, Endocrinologist,1 Professor of 
Medicine2
1 Epworth and Alfred Hospitals, Melbourne VIC.
2 Monash University, Melbourne, VIC..
jrs@netspace.net.au
1 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust
2007; 186: 76-79. 
2 Dowden JS. Product information past perfect
[editorial]. Med J Aust 2007; 186: 51-52. 
3 Therapeutic Goods Administration. Initial discussion
paper: improving access to prescription medicines
information. Apr 2005. http://www.tga.gov.au/consult/
2005/accesspmi.pdf (access Mar 2007). ❏
Call in independent 
information sources
John S Dowden
IN REPLY: The publications reviewed in
Stockigt’s article1 are compendia of product
information (PI). Their currency therefore
relies on manufacturers keeping the PI up to
date. A short scan quickly shows that the PI
of some brands has apparently not needed
amending for more than 5 years. Examples
include certain brands of digoxin (last
updated in 2000), roxithromycin (2000),
levamisole (1999), levocabastine (1998),
pindolol (1993) and ergometrine (1991).
Many monthly changes to PI may be made,
but, as stated in my editorial,2 it is not always
clear whether these changes are substantial
amendments or minor variations. To assess
whether PI reflects current practice would
require Stockigt’s research to be replicated with
other drug classes.
As PI is brand-specific, the amount of
comparative information it contains is lim-
ited. This is where information sources inde-
pendent of the pharmaceutical industry, such as
the Australian medicines handbook (http://
www.amh.net.au/), Therapeutic guidelines (http://
www.tg.com.au/), and the National Prescribing
Service (http://www.nps.org.au/) can assist.
John S Dowden, Editor in Chief
Australian Prescriber, Canberra, ACT.
jdowden@nps.org.au
1 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust
2007; 186: 76-79. 
2 Dowden JS. Product information past perfect
[editorial]. Med J Aust 2007; 186: 51-52. ❏484 MJA • Volume 186 Number 9 • 7 May 2007
MATTERS ARISINGMedicines and breastfeeding: 
information is available on 
safe use
Lisa H Amir
TO THE EDITOR: In his review of drug
information for thyroid-related medications,
Stockigt noted the “outdated advice that
antithyroid drugs are not compatible with
breastfeeding.”1 However, outdated product
information is not unique to antithyroid
drugs. Product information rarely states that
the drug is safe or advisable for breastfeed-
ing women.
Many women receive medicines in the
postpartum period: a UK study found that
54% of women were given a drug in hospital
and 55% were given a prescription by their
general practitioner.2 Yet many breastfeeding
women who need medicines are being given
incorrect advice, as illustrated by the experi-
ence of my podiatrist, Janet.
Breastfeeding was going well when, at 4
months postpartum, Janet fell down a flight
of stairs. Neither the ambulance officers nor
the metropolitan emergency department reg-
istrar were willing to administer any pain
relief except paracetamol (“unless you are
prepared to wean”) — although Janet was in
excruciating pain with a fractured 12th rib.
At 7 months postpartum, Janet was hyper-
tensive despite treatment. Regardless of her
strong desire to continue breastfeeding, her
GP and specialist informed her that she
needed to change medication and therefore
would have to stop breastfeeding.
Janet’s case illustrates two issues: firstly, a
breastfeeding woman was denied necessary
medication because she was breastfeeding, and
secondly, her infant was denied continued
breastfeeding because of maternal medication.
Apparently none of the health professionals
sought expert help with decision making sur-
rounding medicines and breastfeeding. Janet
encouraged me to use her story to educate
other health professionals.
For the vast majority of maternal medica-
tions, the amount of medication an infant
would receive through breastfeeding is less
than 1% of an infant dose. In general, if the
medication is safe to use in infants, it will be
safe for the breastfeeding mother. Only a small
number of medications are contraindicated
during breastfeeding: these include antineo-
plastic agents, ergotamine, methotrexate,
cyclosporin, and radiopharmaceuticals.3
Information is available about safe use of
medicines while breastfeeding (Box). The
sources listed in the Box have reviewed the
available evidence on individual drugs and
given recommendations on whether they are
safe to use during lactation. In general terms,
they have followed the recommendations for
evaluating appropriateness of off-label medi-
cines as suggested by a recent New South
Wales working party.4 Medicines used during
pregnancy are given safety ratings and the
information is available online.5 Australian
clinicians need to access such guidance in
relation to safe prescribing for breastfeeding
women.
Lisa H Amir, Health Professional Research 
Fellow
Mother and Child Health Research, La Trobe 
University, Melbourne, VIC.
l.amir@latrobe.edu.au
1 Stockigt JR. Barriers in the quest for quality drug
information: salutary lessons from TGA-approved
sources for thyroid-related medications. Med J Aust
2007; 186: 76-79. 
2 Jones W, Brown D. The medication vs breastfeeding
dilemma. Br J Midwifery 2003; 11: 550-555.
3 American Academy of Pediatrics Committee on
Drugs. Transfer of drugs and other chemicals into
human milk. Pediatrics 2001; 108: 776-789.
4 Gazarian M, Kelly M, McPhee JR, et al. Off-label use of
medicines: consensus recommendations for evaluating
appropriateness. Med J Aust 2006; 185: 544-548. 
5 Therapeutic Goods Administration Australian Drug
Evaluation Committee. Prescribing medicines in
pregnancy. An Australian categorisation of risk of
drug use in pregnancy. 4th ed. Canberra: Common-
wealth Department of Health and Aged Care, 1999.
Sources of information on medicines for breastfeeding women
Reference books
Pharmacy Department, Royal Women’s Hospital, Melbourne. Drugs and breastfeeding. 
Melbourne: RWH, 2004 (available for sale: tel: 03 9344 2484)
Hale TW. Medications and mothers’ milk. 12th ed. Amarillo, Tex: Pharmasoft Medical Publishing, 
2006 (available for sale at: http://neonatal.ttuhsc.edu/lact)
Websites
Drugs and lactation database (LactMed), a new searchable website set up by the US National 
Library of Medicine (http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT)
World Health Organization. Breastfeeding and maternal medication (http://www.who.int/
child-adolescent-health/New_Publications/NUTRITION/BF_Maternal_Medication.pdf)
Telephone advice
Pharmacy departments of tertiary maternity hospitals
Drug Information Centre, Pharmacy Department, Royal Women’s Hospital, Melbourne 
(tel: 03 9344 2277)  ◆MJA • Volume 186 Number 9 • 7 May 2007 485
